Method Of Screening A Library Patents (Class 506/7)
-
Publication number: 20130261006Abstract: A method of generating a hyperpigmentation condition gene expression signature for use in identifying connections between perturbagens and genes associated with a skin pigmentation condition. The method includes providing a gene expression profile for a reference sample of human skin cells not affected with a pigmentation condition; generating a gene expression profile for a sample of human skin cells from a subject exhibiting the hyperpigmentation condition; comparing the expression profiles to determine a gene expression signature that includes a set of differentially expressed genes; assigning an identifier to each gene constituting the gene expression signature and ordering the identifiers according to the direction of differential expression to create one or more gene expression signature lists; and storing the one or more gene expression signature lists on at least one computer readable medium.Type: ApplicationFiled: March 27, 2013Publication date: October 3, 2013Applicant: The Procter & Gamble CompanyInventors: Tomohiro HAKOZAKI, Wenzhu ZHAO, Robert Lloyd BINDER, Jun XU
-
Patent number: 8546146Abstract: Process for evaluating a plurality of refinery feedstocks, by providing an array of refinery feedstocks, the array having at least a plurality of different refinery feedstocks, and fractionating each of the refinery feedstocks in the array, either in parallel or in a rapid serial fashion, to produce a further array having a plurality of fractions with different chemical and/or physical properties, each fraction being representative of a process stream that might be present in a refinery. Each of the plurality of fractions is analyzed to determine one or more chemical and/or physical properties of the fractions, the analyzes being performed at least partially in parallel.Type: GrantFiled: September 14, 2005Date of Patent: October 1, 2013Assignee: BP Oil International LimitedInventors: Graham Butler, John William Couves, Paul Greenough, Nicholas John Gudde, Michael Graham Hodges
-
Publication number: 20130251751Abstract: The invention relates to a method for identifying immunoreactive peptides. According to said method, a sample of tumorous and corresponding healthy tissue is first provided, the tumor-specific expression profile is subsequently determined and antigenic peptides are isolated from the tumorous tissue and analyzed. The respective data that has been obtained is then matched and peptides are identified on the basis of said data.Type: ApplicationFiled: February 22, 2013Publication date: September 26, 2013Applicant: IMMATICS BIOTECHNOLOGIES GMBHInventors: Toni WEINSCHENK, Hans Georg RAMMENSEE
-
Publication number: 20130244889Abstract: The present invention is directed to a construct for promoting absorption of molecules by a cell and the application thereof in drug and gene delivery. The present invention further describes topographical modulation of endocytosis for drug and gene delivery.Type: ApplicationFiled: September 4, 2012Publication date: September 19, 2013Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: King Fai Evalyn YIM, Hong Yee LOW, Tanu Suryadi KUSTANDI, Kim Kiat TEO, Seok Hong GOH
-
Patent number: 8536099Abstract: According to various embodiments, a method is provided that comprises washing an array of DNA-coated beads on a substrate, with a wash solution to remove stacked beads from the substrate. The wash solution can include inert solid beads in a carrier. The DNA-coated beads can have an average diameter and the solid beads in the wash solution can have an average diameter that is at least twice the diameter of the DNA-coated beads. The washing can form dislodged DNA-coated beads and a monolayer of DNA-coated beads. In some embodiments, first beads for forming an array are contacted with a poly(ethylene glycol) (PEG) solution comprising a PEG having a molecular weight of about 350 Da or less. In some embodiments, slides for forming bead arrays are provided as are systems for imaging the same.Type: GrantFiled: August 31, 2010Date of Patent: September 17, 2013Assignee: Life Technologies CorporationInventors: Mark Oldham, George Fry, Christina Inman, John Bridgham, Timothy Hunkapillar, Charles Vann
-
Patent number: 8536100Abstract: The invention relates to a method for analysing interactions of a nucleic acid with at least one polypeptide, comprising (a) providing a reaction vessel with a composition comprising cross-linked complexes comprising at least one nucleic acid and at least one polypeptide; (b) immobilizing at least part of the cross-linked complexes to the reaction vessel; (c) at least partially reversing said cross-links in said immobilized complexes by performing a heat incubation step thereby at least partially releasing the nucleic acids from the complexes; (d) analyzing the released nucleic acid. wherein steps (a) to (d) are performed in one reaction vessel. Also provided are specific reaction vessels and kits.Type: GrantFiled: March 13, 2009Date of Patent: September 17, 2013Assignee: Qiagen GmbHInventor: Franz Narz
-
Publication number: 20130237430Abstract: The present invention relates to a protein or peptide printing method, comprising (a) a step for preparing nucleic acids and a cell-free protein synthesis system in an engraved plate composed of microscopic grooves having a specific opening shape, (b) a step for superimposing a substrate on the engraved plate so as to contact a protein or peptide to be synthesized in the microscopic grooves, and (c) a step for synthesizing the protein or peptide from the nucleic acids using the cell-free protein synthesis system in the microscopic grooves, and immobilizing the protein or peptide on the substrate along the specific opening shapes of the microscopic grooves.Type: ApplicationFiled: February 21, 2013Publication date: September 12, 2013Applicant: The University of TokyoInventors: Takanori Ichiki, Manish Biyani, Hirofumi Shiono
-
Publication number: 20130225424Abstract: The present disclosure provides methods for predicting the sensitivity (e.g., responsiveness) of a cell and/or biological sample obtained from a subject (e.g., a human) to a drug (e.g., a DHFR inhibitor). Such methods may comprise determining the presence or absence of one or more Ras mutations and/or determining the presence or absence of an amplification of the Ras gene in the cell and/or biological sample. The methods may be used to predict the responsiveness of a subject to treatment with a drug.Type: ApplicationFiled: March 3, 2011Publication date: August 29, 2013Applicant: Targeted Molecular Diagnostics, LLCInventor: Sarah S. Bacus
-
Publication number: 20130225425Abstract: The application provides methods of modulating NR2F6 in a cell or animal in need thereof by administering an effective amount of a NR2F6 modulator.Type: ApplicationFiled: October 15, 2012Publication date: August 29, 2013Inventors: Christine Victoria Ichim, Richard Alexander Wells
-
Publication number: 20130217639Abstract: The present invention provides a compound selected from compound of formula (I), pharmaceutically acceptable salts of compound of formula (I), and pharmaceutically acceptable prodrugs of compound of formula (I), and a composition comprising the compound of the above and a pharmaceutically acceptable excipient. The present invention also provides a method for preparing a compound that activates natural killer T cells.Type: ApplicationFiled: February 22, 2012Publication date: August 22, 2013Applicant: NATIONAL TSING HUA UNIVERSITYInventors: Chung-Shan Yu, Li-Wu Chiang, Kai-Hsiang Chang, Kuo-Yen Liao, Wen-Chin Su, Yin-Cheng Huang
-
Publication number: 20130217712Abstract: The present invention provides a biomarker that is predictive for the response to treatment with an EGFR inhibitor in cancer patients.Type: ApplicationFiled: April 1, 2013Publication date: August 22, 2013Applicant: Hoffmann-La Roche Inc.Inventor: Hoffmann-La Roche Inc.
-
Publication number: 20130210646Abstract: Described microfluidic technology focused on: 1) direct integration of microfluidic devices with solidified liquid tissue samples, 2) subordination of architectural and operational principles of microfluidic devices specific tissue structure and needs and/or 3) on-chip sample acquisition integrated with the detection measurement within the same device. In contrast to conventional methods of off-chip sample prep and subsequent insertion into a detection device, new applications are possible on solidified liquid or solid tissue samples, such as in situ PCR.Type: ApplicationFiled: February 8, 2013Publication date: August 15, 2013Applicants: California Institute of Technology, University of Southern CaliforniaInventors: University of Southern California, California Institute of Technology
-
Publication number: 20130210647Abstract: Disclosed are methods of using phagocytic cells alone, or in combination with non-phagocytic cells, in the diagnosis, prognosis, or monitoring of cardiovascular diseases or conditions. Further disclosed are methods of using phagocytic cells alone or in combination with non-phagocytic cells to identify markers of cardiovascular diseases or conditions.Type: ApplicationFiled: July 22, 2011Publication date: August 15, 2013Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventor: Amin I. Kassis
-
Publication number: 20130203611Abstract: An automatic slide loading device for microarray scanner comprises slide holders (1), a carrier device (2) and a positioning chamber (3), wherein the slide holder (1) can hold microarray slides (6) and the slide holder (1) is placed out of the scanning platform of the microarray scanner when the microarray scanner is in off work state, wherein the carrier device (2) is connected to the positioning chamber (3) and the carrier device (2) can load the slide holder (1) into the positioning chamber (3), wherein the positioning chamber (3) is placed above the scanning platform of the microarray scanner and is used to precisely locate the working surface of the microarray slides (6) in the slide holder (1).Type: ApplicationFiled: August 5, 2011Publication date: August 8, 2013Applicants: Tsinghua University, CapitalBio CorporationInventors: Hang Li, Huihui Teng, Danyang Mei, Wenjun Wang, Gang Li, Xiaokun Qin, Zhengde Feng, Dong Wang, Jing Cheng
-
Publication number: 20130203612Abstract: The present invention relates to a reliable method of prediction of sepsis in humans after a trauma, wherein the level of pancreatic stone protein/regenerating protein (PSP/reg) is determined in serum, and a high level is indicative of the development of sepsis at early stages of the disease. Furthermore a method of determination of PSP/reg levels in serum is described.Type: ApplicationFiled: March 29, 2013Publication date: August 8, 2013Applicant: UNIVERSITAET ZUERICHInventors: Rolf Graf, Daniel Bimmler, Marius Keel
-
Patent number: 8501668Abstract: The invention provides a porous nanoscale membrane. In one embodiment, the membrane can be used as a filtration device to screen agents that disrupt or prevent molecular interactions. In one embodiment, the membrane allows for screening agents that disrupt or prevent molecular interactions using a small sample volume with efficient high-throughput screening applications.Type: GrantFiled: September 9, 2010Date of Patent: August 6, 2013Assignee: University of RochesterInventors: James L. McGrath, Harold C. Smith
-
Patent number: 8486865Abstract: Methods are provided for, inter alia, detecting nucleic acid molecules resistant to degradation, such as a plurality of RNA molecules bound to a ribosome, using various technologies including deep sequencing.Type: GrantFiled: November 3, 2009Date of Patent: July 16, 2013Assignee: The Regents of the University of CaliforniaInventors: Jonathan Weissman, Nicholas Ingolia, Sina Ghaemmaghami, John Newman
-
Publication number: 20130178375Abstract: This invention provides methods of using phagocytic cells alone or in combination with non-phagocytic cells in the diagnosis, prognosis, or monitoring of neurological or neuropsychiatric diseases or conditions. The invention also provides methods of using phagocytic cells alone or in combination with non-phagocytic cells to identify markers of neurological or neuropsychiatric diseases or conditions. Provided are methods of using phagocytic cells alone or in combination with non-phagocytic cells in the diagnosis, prognosis, or monitoring of neurological or neuropsychiatric diseases or conditions. Also provided are methods of using phagocytic cells alone or in combination with nonphagocytic cells to identify markers of neurological or neuropsychiatric diseases or conditions.Type: ApplicationFiled: July 22, 2011Publication date: July 11, 2013Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventor: Amin I. Kassis
-
Publication number: 20130177577Abstract: A method to modulate MHC class I gene expression by modulating NLRC5 expression and/or NLRC5 activity in a subject is provided. The method comprises administering to the subject a compound HLA-A HLA-B that modulates NLRC5 expression and/or NLRC5 activity in an amount effective to modulates MHC class I gene expression. Also described is a screen for compounds that modulate NLRC5 expression. Candidate compounds are tested for their ability to modulate NLRC5 expression.Type: ApplicationFiled: July 12, 2011Publication date: July 11, 2013Applicant: Dana-Farber Cancer Institute, Inc.Inventors: Koichi S. Kobayashi, Torsten B. Meissner, Amy Li
-
Publication number: 20130178376Abstract: Methods for improved quality control of nucleic acid containing biological samples utilized in high-throughput situations such as biorepositories engaged in the collection, processing, storage, distribution and analysis of such samples are disclosed.Type: ApplicationFiled: August 8, 2011Publication date: July 11, 2013Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Jay A. Tischfield, Andrew I. Brooks
-
Patent number: 8481324Abstract: The present invention provides a system containing an array of chemically sensitive sensors based on coated single walled carbon nanotubes, for measuring volatile organic compounds indicative of renal failure. Methods of breath analysis for diagnosing chronic, acute and end-stage renal failure are disclosed.Type: GrantFiled: December 2, 2009Date of Patent: July 9, 2013Assignee: Technion Research and Development Foundation Ltd.Inventors: Hossam Haick, Zaid Abassi, Farid Nakhoul
-
Publication number: 20130172201Abstract: A method for sequencing a polynucleotide strand by using sequencing-by-synthesis techniques. To address the problem of incomplete extension (IE) and/or carry forward (CF) errors that can occur in sequencing-by-synthesis reactions, an alternative flow ordering of dNTPs is used. In contrast to conventional flow orderings, the dNTPs are flowed in an ordering that is not a continuous repeat of an ordering of the four different dNTPs. This alternate flow ordering may reduce the loss of phasic synchrony in the population of template polynucleotide strands that result from IE and/or CF errors.Type: ApplicationFiled: November 29, 2012Publication date: July 4, 2013Applicant: LIFE TECHNOLOGIES CORPORATIONInventor: LIFE TECHNOLOGIES CORPORATION
-
Publication number: 20130172200Abstract: A reagent for detecting gene product, the reagent comprising a probe or chemical modulation that specifically binds to an alternative splicing junction of a gene product of human PTCH1 gene, the expression of the gene product from gene products of the human PTCH1 gene being varied due to the unusual alternative splicing, for use for measuring the abundance of the gene product contained in a human sample.Type: ApplicationFiled: November 27, 2012Publication date: July 4, 2013Applicant: Sekisui Medical Co., Ltd.Inventors: Masato MAEKAWA, Takeshi Uramoto
-
Publication number: 20130165329Abstract: A multimode detection system for detecting one or more samples is provided. The detection system comprises an electromagnetic radiation source, a reference arm, and a sample arm comprising a sensing substrate having a plurality of sample fields, wherein the sample fields are configured to receive the one or more samples. The system further comprises a phase difference generator configured to introduce pathlength differences in the reference arm, sample arm, or both, a spatial light modulator operatively coupled to the reference arm, sample arm, or both, wherein the spatial light modulator is configured to modulate incident radiation, resultant radiation, or both in the reference arm, sample arm, or both, and an imaging spectrometer configured to discriminate between two or more spatially separated sample en two or more spatially separated sample fields.Type: ApplicationFiled: December 22, 2011Publication date: June 27, 2013Applicant: GENERAL ELECTRIC COMPANYInventors: Sameer Dinkar Vartak, Sandip Maity, Rajesh Veera Venkata Lakshmi Langoju, Abhijit Vishwas Patil
-
Patent number: 8470745Abstract: Methods for isolating and using multi-protein complexes that are biologically active are provided. The complexes contain one or more proteins of interest (e.g. a receptor, ion channel, etc.) and associates scaffolding proteins such as phosphatases, kinases and post synaptic density components. Buffers that do not contain denaturing agents and which may be used to isolate the multi-protein complexes are also provided, as are protein arrays containing the biologically active multi-protein complexes. The protein arrays may be used, for example, for high throughput screening assays.Type: GrantFiled: February 10, 2012Date of Patent: June 25, 2013Inventor: Karima Ferrani-Kile
-
Publication number: 20130157877Abstract: The invention relates to biochips 1 comprising a substrate 2, wherein said substrate comprises at the surface thereof isolated regions 3 for the anchoring of a nucleic acid molecule, said isolated regions having an area of less than 1 ?m2, and the space 4 between two isolated regions being at least equal to the square root of the value of said area of said isolated regions.Type: ApplicationFiled: September 1, 2011Publication date: June 20, 2013Applicants: Institut National Des Sciences Appliquees De Toulouse, Centre National De La Recherche Scientifique-CnrsInventors: Thomas Plenat, Laurence Salome, Catherine Tardin, Christophe Thibault, Emmanuelle Trevisiol, Christophe Vieu
-
Publication number: 20130143748Abstract: Provided is a method of measuring the expression level of FSTL3 gene in a biological sample and correlating the measured expression level with the detection of a risk of developing diabetes. Also provided is a method of measuring the expression level of FSTL3 gene in an individual with a BMI value less than 25 not clinically determined as obesity and correlating the measured expression level with the detection of a risk of developing obesity. Further provided is a method of measuring the expression level of FSTL3 gene in an individual with a BMI value less than 25 and correlating the measured expression level with the detection of a risk of developing diabetes. Further provided is a method of measuring an inhibin ?B gene expression level and correlating the ratio of expression level of FSTL3 gene to inhibin ?B gene with the detection of a risk of developing obesity or diabetes.Type: ApplicationFiled: May 27, 2011Publication date: June 6, 2013Applicants: SEKISUI MEDICAL CO., LTD., THE UNIVERSITY OF TOKYOInventors: Takashi Kadowaki, Kohjiro Ueki, Yukiko Okazaki, Matthias Bluher, Sumiko Ozawa
-
Publication number: 20130143747Abstract: Methods and compositions involving molecular markers for the detection and characterization of cancer in a patient are provided.Type: ApplicationFiled: December 5, 2011Publication date: June 6, 2013Applicant: Myriad Genetics, IncorporatedInventors: Alexander Gutin, Jerry Lanchbury, Susanne Wagner, Victor Abkevich
-
Publication number: 20130137589Abstract: The methods and compositions provided herein relate to the discovery of 13 STR markers, found on the human Y chromosome, having surprisingly high mutation rates when compared with 173 other Y-STR markers known today. The set of RM-Y-STRs may overcome the current dilemma of Y-chromosome analysis in forensic applications due to their extraordinary mutation properties. Embodiments of the invention include methods for allelic determination of rapidly-mutating Y-STR markers, amplification primers for the analysis of rapidly-mutating Y-STR markers, allelic ladders for analysis of rapidly-mutating Y-STR markers, and kits for the analysis of rapidly-mutating Y-STR markers.Type: ApplicationFiled: September 10, 2010Publication date: May 30, 2013Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Rixun FANG, Manohar FURTADO, Manfred KAYSER, Kaye BALLANTYNE
-
Publication number: 20130139278Abstract: Plants, plant cells, plant material, seed of plants and regenerated plants comprising a nucleic acid molecule that encodes an amino acid sequence which confers at least one improved characteristic to said plants, plant cells, plant material, seed of plants and regenerated plants as compared to wild-type plants cultivated under identical conditions.Type: ApplicationFiled: September 10, 2012Publication date: May 30, 2013Applicant: Ceres, Inc.Inventors: Nickolai ALEXANDROV, Vyacheslav Brover, Peter Mascia, Ken Feldmann
-
Patent number: 8450247Abstract: Eukaryotic cell display libraries for use in panning processes comprising expressed biomolecules for specific and selective binding and enrichment to solid material surfaces including, for example, metal, magnetic, and semiconducting surfaces. Display can be regulated. Peptide and protein display on yeast cells are preferred. Solid materials can be fabricated in the presence of cell display libraries which have been subjected to panning against the solid materials. Nanoparticles can be grown in the presence of the biomolecules from reactive precursors. The nanoparticles can show quantum confinement effects. Self-healing films can be prepared.Type: GrantFiled: February 7, 2005Date of Patent: May 28, 2013Assignee: Massachusetts Institute of TechnologyInventors: Beau R. Peelle, Angela M. Belcher, Karl Dane Wittrup, Eric Krauland
-
Publication number: 20130130923Abstract: Provided are methods for identifying the presence or absence of a chromosome abnormality by which a cell-free sample nucleic acid from a subject is analyzed. In certain embodiments, provided are methods for identifying the presence or absence of a fetal chromosome abnormality in a nucleic acid from cell-free maternal blood.Type: ApplicationFiled: December 20, 2010Publication date: May 23, 2013Applicant: SEQUENOM, INC.Inventors: Mathias Ehrich, Guy Del Mistro, Cosmin Deciu, Yong Qing Chen, Ron Michael McCullough, Roger Chan Tim
-
Publication number: 20130123119Abstract: Disclosed are novel primers for use in the molecular detection of food-threat agents and food-borne pathogens. The primers may be used in combination for the rapid, high-throughput screening PCR-based techniques to simultaneously detect multiple food safety biothreat agents. The multiplex-detection methods have improved sensitivity and specificity for the detection of multiple high-impact food-borne pathogens simultaneously. Real-time PCR assaying techniques using such primers include microarrays and multiplex single-tube arrays, the latter optionally simultaneously with TaqMan probes.Type: ApplicationFiled: November 15, 2011Publication date: May 16, 2013Applicant: TUSKEGEE UNIVERSITYInventors: Woubit Salah ABDELA, Temesgen SAMUEL-TULORE, Teshome YEHUALAESHET
-
Publication number: 20130116137Abstract: A disclosed chemical detection system for detecting a target material, such as an explosive material, can include a cantilevered probe, a probe heater coupled to the cantilevered probe, and a piezoelectric element disposed on the cantilevered probe. The piezoelectric element can be configured as a detector and/or an actuator. Detection can include, for example, detecting a movement of the cantilevered probe or a property of the cantilevered probe. The movement or a change in the property of the cantilevered probe can occur, for example, by adsorption of the target material, desorption of the target material, reaction of the target material and/or phase change of the target material. Examples of detectable movements and properties include temperature shifts, impedance shifts, and resonant frequency shifts of the cantilevered probe. The overall chemical detection system can be incorporated, for example, into a handheld explosive material detection system.Type: ApplicationFiled: July 2, 2012Publication date: May 9, 2013Applicant: Board of Regents of the Nevada System of Higher Education, on behalf of the University of NevadaInventors: Jesse D. Adams, Todd A. Sulchek, Stuart C. Feigin
-
Publication number: 20130117886Abstract: The present invention relates to isolated nucleic acid molecules and their corresponding encoded polypeptides able confer the trait of modulated plant size, vegetative growth, organ number, plant architecture, sterility or seedling lethality in plants. The present invention further relates to the use of these nucleic acid molecules and polypeptides in making transgenic plants, plant cells, plant materials or seeds of a plant having such modulated growth or phenotype characteristics that are altered with respect to wild type plants grown under similar conditions.Type: ApplicationFiled: December 20, 2012Publication date: May 9, 2013Applicant: CERES, INC.Inventor: Ceres, Inc.
-
Publication number: 20130109579Abstract: The methods and compositions provided herein relate to the discovery of 13 STR markers, found on the human Y chromosome, having surprisingly high mutation rates when compared with 173 other Y-STR markers known today. The set of RM-Y-STRs may overcome the current dilemma of Y-chromosome analysis in forensic applications due to their extraordinary mutation properties. Embodiments of the invention include methods for allelic determination of rapidly-mutating Y-STR markers, amplification primers for the analysis of rapidly-mutating Y-STR markers, allelic ladders for analysis of rapidly-mutating Y-STR markers, and kits for the analysis of rapidly-mutating Y-STR markers.Type: ApplicationFiled: September 13, 2012Publication date: May 2, 2013Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Rixun FANG, Manohar Furtado, Manfred Kayser, Kaye Ballantyne
-
Publication number: 20130102479Abstract: We provide for the use of Tbx3 (GenBank Accession Number: NM_005996.3 (SEQ ID NO. 1), NP_005987.3 (SEQ ID NO. 2), NM_016569.3 (SEQ ID NO. 3), NP_057653.3 (SEQ ID NO. 4)) in a method of enhancing or inducing pluripotency in a cell such as a somatic cell. We describe a method of reprogramming a cell, the method comprising modulating the expression and/or activity of Tbx3 in the cell. The cell may become a pluripotent cell such as a stem cell. We further describe a method of causing a cell such as a somatic cell to display one or more characteristics of a pluripotent cell, the method comprising modulating the expression and/or activity of Tbx3 in the cell. The method may further comprise modulating the expression and/or activity of one or more, a combination of or all of Oct4, Sox2 and Klf4 in the cell.Type: ApplicationFiled: November 18, 2010Publication date: April 25, 2013Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Bing Lim, Jianyong Han, Wai-Leong Tam
-
Patent number: 8420309Abstract: Provided are methods of screening test compounds for the ability to alter calcium homeostasis in mammalian cells by experimentally determining if a compound affects CALHM1, CALHM2, or CALHM3 expression or activity. Additionally provided are methods of screening a test compound for the ability to inhibit ERK 1/2 phosphorylation in a mammalian cell. Further provided are methods of screening a test compound for the ability to inhibit amyloid-beta peptide accumulation in a mammalian cell or biological fluid, methods of screening for a test compound that may affect Alzheimer's disease and methods of determining the likelihood that a subject will be diagnosed with Alzheimer's disease. Also provided are isolated and purified mammalian CALHM proteins, vectors comprising a nucleic acid sequence encoding the CALHM1, CALHM2, and CALHM3 proteins, and mammalian cells transfected with the vectors. Additionally, methods of affecting Ca2+ levels in a mammalian cell are provided.Type: GrantFiled: August 8, 2008Date of Patent: April 16, 2013Assignees: The Feinstein for Medical Research, Cornell Research Foundation, Inc.Inventors: Philippe Marambaud, Fabien Campagne
-
Publication number: 20130072387Abstract: The present invention provides methods for concentrating and pooling liquid suspensions of biological specimens containing analytes of interest in a dry state. The dried biological specimens containing analytes of interest are reconstituted and released from the matrix for subsequent analysis in concentrated form.Type: ApplicationFiled: November 16, 2012Publication date: March 21, 2013Applicant: VIVEBIO, LLCInventor: VIVEBIO, LLC
-
Publication number: 20130072388Abstract: Provided are novel nucleotides, nucleoside, and their derivatives described herein, that can be used in DNA sequencing technology and other types of DNA analysis. In one embodiment, the nucleotide or nucleoside with an unprotected 3?-OH group is derivatized at the nucleobase to include a fluorescent dye attached via a linker to a photocleavable terminating group. The photocleavable-fluorescent group is designed to terminate DNA synthesis as well as be cleaved so that DNA oligomers can be sequenced efficiently in a parallel format. The design of such rapidly cleavable fluorescent groups on nucleotides and nucleosides can enhance the speed and accuracy of sequencing of large oligomers of DNA in parallel, to allow rapid whole genome sequencing, and the identification of polymorphisms and other valuable genetic information, as well as allowing further manipulation and analysis of nucleic acid molecules in their native state following cleavage of the fluorescent group.Type: ApplicationFiled: August 23, 2012Publication date: March 21, 2013Inventors: Weidong WU, Vladislav A. Litosh, Brian P. Stupi, Michael L. Metzker
-
Publication number: 20130058870Abstract: The invention relates to nanocrystals, containing one or more metals as defined in the specification; having a size of 2 to 200 nm; having a defined, three-dimensional polyhedral structure, optionally functionalized by ligands and/or embedded crystals. The invention further relates to monodisperse assemblies of such nanocrystals, to formulations and devices comprising such nanocrystals as well as to the manufacture and use thereof.Type: ApplicationFiled: May 11, 2011Publication date: March 7, 2013Applicant: ETH ZURICHInventors: Christophe Jan Lacroix, Christophe Chassard, Marcus Yaffee
-
Publication number: 20130058954Abstract: The present invention relates to methods of diagnosis and treatment of corneal ectasia following refractive surgery, keratoconus or pellucid marginal degeneration in a subject by determining or modulating the level of expression of molecules associated with the Wnt signalling pathway. Marker molecules of the present invention include SFRP1, PITX2, LEF1, WNT16 and WNT5A.Type: ApplicationFiled: December 2, 2010Publication date: March 7, 2013Applicant: THE UNIVERSITY OF SYDNEYInventors: Gerard Sutton, John McAvoy, Michele Madigan
-
Publication number: 20130052160Abstract: The present invention relates to the fields of genetics, immunology and medicine. The present invention more specifically relates to in vitro or ex vivo methods for determining the susceptibility to a cancer treatment of a subject having a tumour. These methods comprise a step of determining the ability of the treatment, of the subject and/or of the tumour to induce an anticancer immune response, the inability of at least one of the treatment, the subject and the tumor to induce an anticancer immune response being indicative of a resistance of the subject to the therapeutic treatment of cancer. Inventors in particular identify genes specific of a human subject or of cancerous cells which can be used to predict or assess the sensitivity of a subject to a treatment of cancer. The invention also relates to particular compounds capable of activating or enhancing the immune system of a particular subject, when the subject is exposed to a therapeutic treatment of cancer or before such an exposition.Type: ApplicationFiled: April 1, 2011Publication date: February 28, 2013Applicant: INSTITUT GUSTAVE ROUSSYInventors: Laurence Zitvogel, Guido Kroemer, Nicolas Delahaye, Yuting Ma, Oliver Kepp
-
Publication number: 20130045877Abstract: A method of manufacturing a substrate is provided. The method comprises, in some aspects, a) providing a support; b) forming a template by attaching a plurality of polymeric nanoparticles some or all having a core-shell structure to the support, wherein the core comprises a first polymer and the shell comprises a second polymer; and c) forming the metal nanoarray substrate by attaching a plurality of metallic nanoparticles to at least some of the polymeric nanoparticles of the template. A biosensor comprising a substrate manufactured by the method, and a method for the detection of an analyte in a sample by surface enhanced Raman spectroscopy (SERS) is also provided.Type: ApplicationFiled: August 17, 2012Publication date: February 21, 2013Applicant: Agency for Science, Technology and ResearchInventors: Fung Ling Yap, Sivashankar Krishnamoorthy, Praveen Thoniyot, Vignesh Suresh, Sanghamitra Dinda
-
Publication number: 20130045875Abstract: Methods of characterizing a nucleic acid library by digital assay.Type: ApplicationFiled: July 30, 2012Publication date: February 21, 2013Applicant: BIO-RAD LABORATORIES, INC.Inventors: Serge Saxonov, Svilen S. Tzonev, Michael Y. Lucero, Ryan T. Koehler, Benjamin J. Hindson
-
Publication number: 20130045188Abstract: Methods of inhibiting metastasis in cancer patients are provided, wherein the methods comprise reducing TGF? signaling, for example, by reducing TGF receptor II expression in myeloid cells. Vectors comprising a TGF? receptor II RNAi nucleic acid sequence operably linked to a myeloid specific promoter also are provided. A method of diagnosing cancer in an individual by determining TGF? receptor II expression in myeloid cells in the individual is provided. Additionally, a method of modulating TGF? activity in myeloid cells in a cancer patient comprising administering a regulator of at least one of the GSK3 and PI3K pathways to the patient is provided.Type: ApplicationFiled: August 20, 2012Publication date: February 21, 2013Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventor: Li Yang
-
Publication number: 20130045876Abstract: The invention provides for sequencing a nucleic acid molecule based on the detection of base incorporation by the release of pyrophosphate (PPi) using a new enzyme system comprising adenosine diphosphate (ADP)-glucose pyrophosphorylase (AGPase) and its substrate ADP-glucose.Type: ApplicationFiled: February 21, 2011Publication date: February 21, 2013Applicant: Agency for Science Technology and ResearchInventors: Sanket Goel, Min Gong, Abdur Rub Abdur Rahman, Shihui Foo
-
Patent number: 8377852Abstract: A method of preparing a substrate with a composition comprising (i) an organoborane initiator and (ii) a radical curable component disposed thereon includes the step of depositing the composition onto the substrate wherein at least one of (i) the organoborane initiator and (ii) the radical curable component is deposited onto the substrate in the form of a gradient pattern. An article comprises the substrate and the gradient pattern formed on the substrate. The gradient pattern is formed from a developed composition comprising the reaction product of (i) the organoborane initiator and (ii) the radical curable component. By forming the gradient pattern on the substrate, combinatorial and high-throughput methods of generating and testing the developed composition are possible, which enable characterization of the developed composition for various physical and chemical properties.Type: GrantFiled: October 24, 2008Date of Patent: February 19, 2013Assignee: Dow Corning CorporationInventors: Dongchan Ahn, Kevin Wier
-
Publication number: 20130040829Abstract: A method of inducing latency in Mycobacterium permits preparation of an in vitro model system of latent mycobacterial infection. Latency is induced in a pure culture of Mycobacterium by exposing it to multiple stress conditions, including a low nutrient culture medium without glycerol, a low pH, a relatively high level of carbon dioxide and a relatively low gas phase oxygen level. An in vitro model of mycobacterial infection employs macrophages induced from THP1 cells which are then infected with Mycobacterium. The infected macrophages are grown under hypoxic conditions to induce latency in the mycobacteria. The in vitro model of infection is useful in evaluating compounds for activity against latent mycobacteria.Type: ApplicationFiled: August 13, 2012Publication date: February 14, 2013Applicant: University of Central Florida Research Foundation, Inc.Inventors: Pappachan E. Kolattukudy, Tatiana Sirakova, Jaiyanth Daniel, Chirajoti Deb
-
Publication number: 20130040830Abstract: A sample testing vessel may include a flexible plastic tube and a self-sealing injection channel. The flexible plastic tube may have a seal defining a first compartment and a second compartment, wherein the seal comprises a pressure gate providing a fluid-tight seal between first and second compartments and opening upon application of a threshold pressure. The injection channel may be normally substantially free of fluid and capable of fluid communication with the tubule.Type: ApplicationFiled: October 12, 2012Publication date: February 14, 2013Applicant: CHEN & CHEN, LLCInventor: Chen & Chen, LLC